Skip to main content

Advertisement

SpringerLink
Log in

Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors

  • Research Article
  • Published:
Tumor Biology

Abstract

Kallikrein-related peptidases (KLKs) are emerging novel new biomarkers for prognosis, diagnosis and therapeutic intervention of cancer. Kallikrein-related peptidase 6 (KLK6) has the highest expression in normal brain among other tissues. Although its expression has been extensively studied in many types of cancer and in neurodegenerative diseases, very little is known for its expression in intracranial tumors. In the present study, 73 intracranial tumor samples were examined for KLK6 messenger ribunucleic acid (mRNA) gene expression using quantitative real-time polymerase chain reaction. Statistical analysis revealed the significant association of KLK6 expression with clinical and pathological parameters. Follow-up information was available for a median time of 20 months (range 1–59 months). KLK6 is expressed more frequently in tumors of high malignancy like the glioblastomas (70.6 %) and less in tumors of low malignancy like the meningiomas (12.5 %). KLK6 positive expression is associated with tumor grade (p < 0.001), malignancy status (p < 0.001), and tumor histologic type (p = 0.001). Cox proportional hazard regression model using univariate analysis revealed for the first time that positive KLK6 expression is a significant factor for disease-free survival (DFS; p = 0.041) of patients suffering from intracranial tumors. Kaplan–Meier survival curves demonstrated that negative KLK6 expression is significantly associated with longer DFS (p = 0.032). KLK6 gene expression may have clinical utility as a marker of unfavorable prognosis for intracranial tumors, and consequently, it could be used as target for therapeutic intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6–29.

    Article  CAS  PubMed  Google Scholar 

  2. Wen PY, Kesari S. Malignant gliomas in adults. New Engl J Med. 2008;359:492–507.

    Article  CAS  PubMed  Google Scholar 

  3. Davis F, Malmer B, Aldape K, Barnholtz-Sloan JS, Bondy ML, Brannstrom Th, et al. Issues of diagnostic review in brain tumor studies: From the brain tumor epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2008;17:484–9.

    Article  PubMed  Google Scholar 

  4. Adamson C, Kanu OO, Mehta AI, Di CH, Lin N, Mattox AK, et al. Glioblastoma multiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18:1061–83.

    Article  CAS  PubMed  Google Scholar 

  5. Lu Ch, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem. 2008;312:71–80.

    Article  CAS  PubMed  Google Scholar 

  6. Arribas Alpuente L, Menendez Lopez A, Yaya Tur R. Glioblastoma: Changing expectations. Clin Transl Oncol. 2011;13(4):240–8.

    Article  PubMed  Google Scholar 

  7. Claus EB, Bondy ML, Schildkraut JM, Wiemels J, Wrensch M, Black PΜ. Epidemiology of intra-cranial meningioma. Neurosurgery. 2005;57:1088–95.

    Article  PubMed  Google Scholar 

  8. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010;99:379–91.

    Article  CAS  PubMed  Google Scholar 

  9. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumor suppression. Nat Rev Cancer. 2007;7:800–8.

    Article  CAS  PubMed  Google Scholar 

  10. Borgono CA, Diamandis EP. The emerging roles of human kallikreins in cancer. Nat Rev Cancer. 2004;4:76–90.

    Article  Google Scholar 

  11. Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta. 2007;1776:22–31.

    CAS  PubMed  Google Scholar 

  12. Lu Y, Papagerakis P, Yamakoshi Y, Hu JCC, Bartlett JD, Simmer JP. Functions of KLK4 and MMP-20 in dental enamel formation. Biol Chem. 2008;389:695–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Scarisbrick IA, Limbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegenaration. Biol Chem. 2008;389:739–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Hollenberg MD, Oikonomopoulou K, Hansen KK, Saifeddine M, Ramachandran R, Diamandis EP. Kallikreins and proteinase-mediated signaling: Proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem. 2008;389:643–51.

    Article  CAS  PubMed  Google Scholar 

  15. Shaw JLV, Diamandis EP. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. Biol Chem. 2008;389:681–8.

    CAS  PubMed  Google Scholar 

  16. Smith RS, Gao Jr L, Chao L, Chao J. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008;389:725–30.

    Article  CAS  PubMed  Google Scholar 

  17. Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem. 2009;284:32989–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yousef GM, Tadaaki T. Diamandis EP (2003) Role of kallikrein enzymes in the central nervous system. Clin Chim Acta. 2003;329:1–8.

    Article  CAS  PubMed  Google Scholar 

  19. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: Applications in cancer. Cancer Lett. 2005;224:1–22.

    Article  CAS  PubMed  Google Scholar 

  20. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996;2:624–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Yamashiro K, Tsuruoka N, Kodama S, Tsujimoto M, Yamamura Y, Tanaka T, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta. 1997;1350(1):11–4.

    Article  CAS  PubMed  Google Scholar 

  22. Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer’s disease brain. J Biol Chem. 1997;272:25135–42.

    Article  CAS  PubMed  Google Scholar 

  23. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP. Molecular characterization of zyme/protease M/neurosine (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics. 1999;62:251–9.

    Article  CAS  PubMed  Google Scholar 

  24. Bernett MJ, Blaber SI, Scarisbrick IA, Dhanaraja P, Thompson SM, Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem. 2002;277:24562–70.

    Article  CAS  PubMed  Google Scholar 

  25. Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol. 2001;431:347–61.

    Article  CAS  PubMed  Google Scholar 

  26. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53:1423–32.

    Article  CAS  PubMed  Google Scholar 

  27. Tatebea Η, Watanabeb Υ, Kasaia Τ, Mizunoa Τ, Nakagawaa Μ, Tanakab Μ, et al. Extracellular neurosin degrades α-synuclein in cultured cells. Neurosci Res. 2010;67:341–6.

    Article  Google Scholar 

  28. Ashby EL, Kehoe PG, Love S. Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. Brain Res. 2010;1363:1–10.

    Article  CAS  PubMed  Google Scholar 

  29. Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunol. 2006;178:167–76.

    Article  CAS  PubMed  Google Scholar 

  30. Hebb AL, Bhan V, Wishart AD, Moore CS, Robertson GS. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Curr Drug Discov Technol. 2010;7(2):137–40.

    Article  CAS  PubMed  Google Scholar 

  31. Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 2010;6:269–85.

    Article  CAS  PubMed  Google Scholar 

  32. Shan SJ, Scorilas A, Katsaros D, Diamandis EP. Transcriptional up-regulation of human tissue kallikrein 6 in ovarian cancer: Clinical and mechanistic aspects. Br J Cancer. 2007;96:362–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res. 2005;11:2889–93.

    Article  CAS  PubMed  Google Scholar 

  34. Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, et al. Clinicopathologic and biological significance of KLK6 overexpression in human gastric cancer. Clin Cancer Res. 2005;11:6800–6.

    Article  CAS  PubMed  Google Scholar 

  35. Ruckert F, Hennig M, Petraki CD, Wehrum D, Distler M, Denz A, et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer. 2008;99(9):1484–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. \Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, et al. Human kallikrein 6: A new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005;11(9):3320–5.

    Article  CAS  PubMed  Google Scholar 

  37. Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to mesenchymal transition. Cancer Res. 2009;69(9):3779–87.

    Article  CAS  PubMed  Google Scholar 

  38. Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10, 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223–7.

    Article  CAS  PubMed  Google Scholar 

  39. Krenzer S, Peterziel H, Mauch C, Blaber SI, Blaber M, Angel P, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Invest Dermatol. 2011;131:2281–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ni X, Zhang W, Huabg KC, Wang Y, Ng SK, Mok SC, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer. 2004;91(4):725–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Klucky B, Mueller R, Vogt I, Teurich S, Hartenstein B, Breuhahn K, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration and invasion. Cancer Res. 2007;67:8198–6.

    Article  CAS  PubMed  Google Scholar 

  42. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, et al. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochim Biophys Res Commun. 2003;307:948–55.

    Article  CAS  Google Scholar 

  43. Chosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumor cells. Tumor Biol. 2004;25:193–9.

    Article  Google Scholar 

  44. Bayes A, Tseklenis T, Ventura S, Vendrell J, Aviles FX, Sotiropoulou G. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem. 2004;385:517–24.

    Article  CAS  PubMed  Google Scholar 

  45. Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J, Renner DN, et al. Functional role of kallikrein 6 in regulating immune cell survival. PLoS One. 2011;6(3):1–11. e18376.

    Article  Google Scholar 

  46. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res. 2009;29(8):3269–79.

    CAS  PubMed  Google Scholar 

  47. Prezas P, Scorilas A, Yfanti Ch, Viktorov P, Agnanti N, Diamandis EP, et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem. 2006;387:1607–12.

    CAS  PubMed  Google Scholar 

  48. Talieri M, Pappa E, Scorilas A, Devetzi M, Tsapralis N, Ardavanis A, et al. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. Tumor Biol. 2012. doi:10.1007/s13277-012-0347-x.

  49. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.

    Article  CAS  PubMed  Google Scholar 

  50. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.

    Article  CAS  PubMed  Google Scholar 

  51. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, et al. The spectrum of human kallikrein6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem. 2001;49(11):1431–41.

    Article  CAS  PubMed  Google Scholar 

  52. Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol. 2002;103:351–5.

    Article  PubMed  Google Scholar 

  53. Klein R, Roggendorf W. Increased microglia proliferation separates pilocytic astrocytomas from diffuge astrocytomas: A double labeling study. Acta Neuropathol. 2001;101:245–8.

    CAS  PubMed  Google Scholar 

  54. Leenstra S, Das P, Troost D, Boer OJ, Bosch DA. Human malignant astrocytes express macrophage phenotype. J Neuroimmunol. 1995;56:17–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Cellular Physiology, G. Papanicolaou Research Center of Oncology, Saint Savvas Cancer Hospital, 171, Alexandras Avenue, Athens, 11522, Greece

    Maroulio Talieri, Marita Zoma & Marina Devetzi

  2. Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Athens, 15711, Greece

    Andreas Scorilas

  3. Department of Medical Oncology, Saint Savvas Cancer Hospital, Athens, 11522, Greece

    Alexandros Ardavanis

Authors
  1. Maroulio Talieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marita Zoma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marina Devetzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas Scorilas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandros Ardavanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maroulio Talieri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talieri, M., Zoma, M., Devetzi, M. et al. Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors. Tumor Biol. 33, 1375–1383 (2012). https://doi.org/10.1007/s13277-012-0385-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0385-4

Keywords

Search

Navigation